About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Evaluation of the New Variant 501Y.V2 of COVID-19

NCT04906850·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Centre Hospitalier Régional Metz-Thionville

With

Central Hospital, Nancy, France

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Admission in ICU in February, March or April 2021
Patient with a SARS-CoV-2 positive polymerase-chain reaction test
Patient with 20I/501Y.V1 ("English") or 20H/501Y.V2 ("South African") SARS-CoV-2 variants

You may not be if

Opposed to use data

The record

StatusCompleted

PhaseNo phase

Taking part250

StartedMar 2021

UpdatedJun 2, 2021

Conditions

Where2

CHRU Nancy
Nancy, Meurthe-et-moselle, France
CHR Metz Thionville
Metz, Moselle, France

Clareo Health | Evaluation of the New Variant 501Y.V2 of COVID-19